Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Girard

Showing results (1-10 of 450) with videos related to

Pageof 45
Sort By:
Current Treatment Options in Oncology|October 15, 2022
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung CancerNicolas Girard
Mediastinum (Hong Kong, China)|February 4, 2022
Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?Nicolas Girard
La Revue Du Praticien|December 5, 2018
[Lung cancer: 10 points to remember]Nicolas Girard
Future Oncology (London, England)|August 28, 2019
Optimizing outcomes and treatment sequences in <i>EGFR</i> mutation-positive non-small-cell lung cancer: recent updatesNicolas Girard
Bulletin Du Cancer|June 30, 2015
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No]Nicolas Girard
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Thymic Tumors: Revisiting Autoimmunity to Give a Chance to ImmunotherapyNicolas Girard
Expert Review of Anticancer Therapy|October 19, 2013
Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspectiveNicolas Girard
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50Nicolas Girard
Current Oncology Reports|May 28, 2025
Therapeutic Management of Metastatic Thymoma and Thymic CarcinomaNicolas Girard
Med (New York, N.Y.)|September 14, 2024
EGFR-mutated NSCLC: A roadmap to treatment sequencesNicolas Girard
Pageof 45

Showing results (1-10 of 450) with videos related to

Sort By:
Pageof 45
Current Treatment Options in Oncology|October 15, 2022
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung CancerNicolas Girard
Mediastinum (Hong Kong, China)|February 4, 2022
Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies?Nicolas Girard
La Revue Du Praticien|December 5, 2018
[Lung cancer: 10 points to remember]Nicolas Girard
Future Oncology (London, England)|August 28, 2019
Optimizing outcomes and treatment sequences in <i>EGFR</i> mutation-positive non-small-cell lung cancer: recent updatesNicolas Girard
Bulletin Du Cancer|June 30, 2015
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No]Nicolas Girard
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 24, 2018
Thymic Tumors: Revisiting Autoimmunity to Give a Chance to ImmunotherapyNicolas Girard
Expert Review of Anticancer Therapy|October 19, 2013
Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspectiveNicolas Girard
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
In Patients With Early Stage NSCLC Without Driver Mutation After Surgical Resection and Chemotherapy: Adjuvant Atezolizumab Should Only Be Given for Patients With Programmed Death-Ligand 1 Greater Than or Equal to 50Nicolas Girard
Current Oncology Reports|May 28, 2025
Therapeutic Management of Metastatic Thymoma and Thymic CarcinomaNicolas Girard
Med (New York, N.Y.)|September 14, 2024
EGFR-mutated NSCLC: A roadmap to treatment sequencesNicolas Girard
Pageof 45